ResMed Inc. (RMD) on Decifer

Decifer ranks RMD number 262 of 277 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 19% and it turns most of its profit into real cash.
• Revenue is growing about 10% a year, profits grew 9% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Strong returns around 19% and widening margins are durable but revenue growing 10% a year with no funded role and momentum of 7 out of 35 keep it modest.

The current read

The evidence on RMD lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• GLP-1 & Metabolic Disease Wave: GLP-1 receptor agonists have demonstrated large-scale efficacy in obesity and diabetes, triggering a multi-hundred-billion-dollar demand and capex surge across pharma and diabetes-device makers.

Read the full RMD research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.